Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 2095-2101

  Wiernik, Peter H ^a,b   Sun, Zhuoxin ^b,c   Gundacker, Holly ^d,e   Dewald, Gordon ^b,f   Slovak, Marilyn L ^d,g   Paietta, Elisabeth ^b   Kim, Haesook T ^b,c   Appelbaum, Frederick R ^d,e   Cassileth, Peter A ^b,h   Tallman, Martin S ^b,i  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b Eastern Cooperative Oncology Group   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d Southwest Oncology Group   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f MAYO CLINIC   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Karyotype; T(15; 17)

Indexed keywords

RETINOIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME ABERRATION; DE NOVO ACUTE PROMYELOCYTIC LEUKEMIA; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ABNORMAL KARYOTYPE; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 15; CHROMOSOMES, HUMAN, PAIR 17; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TRETINOIN; YOUNG ADULT;

EID: 84872820174     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0251-7     Document Type: Article

References (26)

1. Schoch C, Haferlach T, Hasse D, Fonatsch C, Löffler H, Schlegelberger B, Staib P, Sauerland MC, Heinecke A, Büchner T, Hiddemann W. Patients with de novo acute myeloid 1eukaemia and complex karyotype aberrations have a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol. 2001; 112:118-26.
2. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-8.
3. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649-56.
4. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-9.
5. Mathews V, Thomas M, Srivastava VM, George B, Srivastava A, Chandy M. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Haematologica. 2007;92:994-5.
6. Agresti A. Exact inference for categorical data: recent advances and continuing controversies. Stat Med. 2002;20:2709-22.
7. Landis RJ, Heyman ER, Koch GG. Average partial association in three-way contingency tables: a review and discussion of alternative tests. Int Stat Rev. 1978;46:237-54.
8. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
9. Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, Swirsky D, Wheatley K, Goldstone A, Burnett A, Solomon E. Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. MRC Adult Leukaemia Working Party. Br J Haematol. 1996;94:557-73.
10. Slack JL, Arthur DC, Lawrence D, Mrózek K, Mayer RJ, Davey FR, Tantravahi R, Pettenati MJ, Bigner S, Carroll AJ, Rao KW, Schiffer CA, Bloomfield CD. Secondary cytogenetic changes in acute promyelocytic leukemia-prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol. 1997;15:1786-95.
11. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American intergroup protocol. Blood. 2002;100:4298-302.
12. Okoshi Y, Akiyama H, Kono N, Matsumura T, Mizuchi D, Mori S, Ohashi K, Sakamaki H. Effect of additional chromosomal abnormalities in acute promyelocytic leukemia treated with alltrans retinoic acid: a report of 17 patients. Int J Hematol. 2001;73: 496-501.
13. O'Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S, Magenis E, Capdeville R, Drucker BJ. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood. 2002;100:1628-33.
14. Mohamed AN, Pemberton P, Zonder J, Schiffer CA. The effect of imatinib mesylate on patients with Philadelphia chromosomepositive chronic myeloid leukemia with secondary chromosomal aberrations. Clin Cancer Res. 2003;9:1333-7.
15. Le Beau MM, Bitts S, Davis EM, Kogan SC. Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia. Blood. 2002; 99:2985-91.
16. Wolman SR, Gundacker H, Appelbaum FR, Slovak ML. Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2002;100:29-35.
17. Xu L, Zhao WL, Xiong SM, Su XY, Zhao M, Wang C, Gao YR, Niu C, Cao Q, Gu BW, Zhu YM, Gu J, Hu J, Yan H, Shen ZX, Chen Z, Chen SJ. Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia. Leukemia. 2001;15:1359-68.
18. Schoch C, Hasse D, Haferlach T, Freund M, Link H, Lengfelder E, Löffler H, Büchner T, Fonatsch C. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol. 1996;94:493-500.
19. De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, Fey M, Rayon C, Huguet F, Soto JJ, Gardin C, Cony Makhoul P, Travade P, Solary E, Fegueux N, Bordessoule D, San Miguel J, Link H, Desablens B, Stomatoullas A, Deconinck E, Geiser K, Hess U, Maloisel F, Castaigne S, Preudhomme C, Chomienne C, Degos L, Fenaux P. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000; 111:801-6.
20. Hernández JM, Martin G, Gutiérrez NC, Cerva J, Ferro MT, Calasanz MJ, Martinez-Climent JA, Luño E, Tomo M, Rayón C, Díaz-Mediavilla J, González M, González-San Miguel JD, Pérez-Esquiza K, Rivas C, Esteve J, Alvarez Midel C, Odriozola J, Ribera JM, Sanz MA. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracycline based protocol. A report of the Spanish group PETHEMA. Haematologica. 2001;86:807-13.
21. Pantic M, Novak A, Marisavljevic D, Djordjevic V, Elezovic I, Vidovic A, Colovic M. Additional chromosome aberrations in acute promyelocytic leukemia: characteristics and prognostic influence. Med Oncol. 2000;17:307-13.
22. Wan TS, Ma SK, Au WY, Liu HS, Chan JC, Chan LC. Trisomy 21 and other chromosomal abnormalities in acute promyelocytic leukemia. Cancer Genet Cytogenet. 2003;140:170-3.
23. Hiorns LR, Swansbury GJ, Mehta J, Min T, Dainton MG, Treleaven J, Powles RL, Catovsky D. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol. 1997;96:314-21.
24. Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pedersen Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosom Cancer. 2002;33:395-400.
25. Liang JY, Wu DP, Liu YJ, Ma QF, Gong JX, Zhu MQ, Xue YQ, Chen ZX. The clinical and laboratory features of acute promyelocytic leukemia: an analysis of 513 cases. Zhonghua Nei Ke Za Zhi. 2008;47:389-92.
26. Lu J, Jiang H, Jiang Q, Bao L, Lu XJ, Zhang Y, Lin W, Liu YR, Huang XJ, Jiang B. Effect of additional chromosome abnormalities on the outcome of newly diagnosed acute promyelocytic leukemia treated with red arsenic sulfide and all-trans retinoic acid plus anthracyclin based protocol. Zhonghua Yi Xue Za Zhi. 2008;88:2254-7.